Veru Enters Supply Agreement With Novo Nordisk for Obesity Study; Shares Surge

MT Newswires Live06-05

Veru (VERU) said Thursday in a regulatory filing that it entered a clinical supply agreement with Novo Nordisk (NVO) to support its phase 2b PLATEAU study evaluating enobosarm in combination with Novo's Wegovy in older adults with obesity undergoing weight loss treatment.

Under the agreement, Novo Nordisk will provide Wegovy free of charge for the study, while Veru will sponsor and conduct the trial and share clinical study updates and insights related to obesity and weight management research, the filing shows.

Veru said it retains global development and commercialization rights to enobosarm, while Novo Nordisk received a right of first negotiation if Veru seeks to develop, commercialize or license enobosarm in combination with Novo Nordisk GLP-1 products in the future.

Shares of Veru rose 155% in Thursday trading.

Price: 5.52, Change: +3.27, Percent Change: +145.47

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2641169473?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 01:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641169473","market":"hk","top_or_hot":-1,"title":"Veru Enters Supply Agreement With Novo Nordisk for Obesity Study; Shares Surge","media":"MT Newswires Live","content":"<html><body><p> Veru (VERU) said Thursday in a regulatory filing that it entered a clinical supply agreement with <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> (NVO) to support its phase 2b PLATEAU study evaluating enobosarm in combination with Novo's Wegovy in older adults with obesity undergoing weight loss treatment.</p><p>Under the agreement, Novo Nordisk will provide Wegovy free of charge for the study, while Veru will sponsor and conduct the trial and share clinical study updates and insights related to obesity and weight management research, the filing shows.</p><p>Veru said it retains global development and commercialization rights to enobosarm, while Novo Nordisk received a right of first negotiation if Veru seeks to develop, commercialize or license enobosarm in combination with Novo Nordisk GLP-1 products in the future.</p><p>Shares of Veru rose 155% in Thursday trading.</p><p>Price: 5.52, Change: +3.27, Percent Change: +145.47</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Veru Enters Supply Agreement With Novo Nordisk for Obesity Study; Shares Surge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVeru Enters Supply Agreement With Novo Nordisk for Obesity Study; Shares Surge\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-05 01:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Veru (VERU) said Thursday in a regulatory filing that it entered a clinical supply agreement with <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> (NVO) to support its phase 2b PLATEAU study evaluating enobosarm in combination with Novo's Wegovy in older adults with obesity undergoing weight loss treatment.</p><p>Under the agreement, Novo Nordisk will provide Wegovy free of charge for the study, while Veru will sponsor and conduct the trial and share clinical study updates and insights related to obesity and weight management research, the filing shows.</p><p>Veru said it retains global development and commercialization rights to enobosarm, while Novo Nordisk received a right of first negotiation if Veru seeks to develop, commercialize or license enobosarm in combination with Novo Nordisk GLP-1 products in the future.</p><p>Shares of Veru rose 155% in Thursday trading.</p><p>Price: 5.52, Change: +3.27, Percent Change: +145.47</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2641169473","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2641169473","pubTimestamp":1780592947,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Veru  said Thursday in a regulatory filing that it entered a clinical supply agreement with Novo Nordisk  to support its phase 2b PLATEAU study evaluating enobosarm in combination with Novo's Wegovy in older adults with obesity undergoing weight loss treatment.Under the agreement, Novo Nordisk will provide Wegovy free of charge for the study, while Veru will sponsor and conduct the trial and share clinical study updates and insights related to obesity and weight management research, the filing shows.Veru said it retains global development and commercialization rights to enobosarm, while Novo Nordisk received a right of first negotiation if Veru seeks to develop, commercialize or license enobosarm in combination with Novo Nordisk GLP-1 products in the future.Shares of Veru rose 155% in Thursday trading.Price: 5.52, Change: +3.27, Percent Change: +145.47","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","NVO":"诺和诺德","BK4557":"大麻股","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4532":"文艺复兴科技持仓","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4599":"减肥药","BK4007":"制药","NVOH":"Novo Nordisk A/S B Shares ADRhedged","BK4584":"避孕概念","BK4585":"ETF&股票定投概念","BK4183":"个人用品","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","VERU":"Veru Inc.","NVOX":"2倍做多NVO ETF-Defiance","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD"},"translate_title":"Veru与诺和诺德签订肥胖研究供应协议；股价飙升","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVOX":0.6,"NVO":1.91,"NVOH":0.6,"VERU":1.96},"content_text":"Veru (VERU) said Thursday in a regulatory filing that it entered a clinical supply agreement with Novo Nordisk (NVO) to support its phase 2b PLATEAU study evaluating enobosarm in combination with Novo's Wegovy in older adults with obesity undergoing weight loss treatment.Under the agreement, Novo Nordisk will provide Wegovy free of charge for the study, while Veru will sponsor and conduct the trial and share clinical study updates and insights related to obesity and weight management research, the filing shows.Veru said it retains global development and commercialization rights to enobosarm, while Novo Nordisk received a right of first negotiation if Veru seeks to develop, commercialize or license enobosarm in combination with Novo Nordisk GLP-1 products in the future.Shares of Veru rose 155% in Thursday trading.Price: 5.52, Change: +3.27, Percent Change: +145.47","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2641169473","isCrawlerRequest":true}